GMI-1687, a highly potent E-selectin antagonist, is being developed as a potential point-of-care treatment for inflammatory diseases with initial focus on sickle cell disease
Single ascending.
05.09.2023 - GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m. ET. A live .
GlycoMimetics (NASDAQ:GLYC – Get Free Report) and Orgenesis (NASDAQ:ORGS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Analyst Ratings This is a summary of recent recommendations […]
Letko Brosseau & Associates Inc Invests $57,000 in GlycoMimetics, Inc (NASDAQ:GLYC) kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Research analysts at StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock. Separately, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of GlycoMimetics in a report on Thursday, August […]